Efficacy and safety of lamivudine treatment in late pregnancy with high HBV DNA: a perspective for mother and infants

Authors

  • Sükran Köse Tepecik Training and Research Hospital, Department of Infectious Diseases and Clinic Microbiology, Turkey
  • Melda Türken Tepecik Training and Research Hospital, Department of Infectious Diseases and Clinic Microbiology, Turkey
  • İlker Devrim Pediatric Infectious Disease Unit
  • Cüneyt Taner izmir Aegean Obstetrics and Gynecology Teaching Hospital, Izmir, Turkey

DOI:

https://doi.org/10.3855/jidc.1398

Keywords:

lamivudine, chronic hepatitis B infection, pregnancy

Abstract

Introduction: Perinatal transmission - from mother to fetus - is one of the main transmission routes of chronic hepatitis B (CHB) infection. Lamivudine therapy has been reported to prevent the replication of hepatitis B virus (HBV) in pregnant women with a high viral load that can lead to perinatal transmission.

Methodology: This study sought to evaluate retrospectively the efficacy and safety of lamivudine treatment in pregnant women with CHB and a high viral load. Biochemical parameters, and virological and serological responses at the 32nd and 36th week of gestation and after labor were recorded. The complications of CHB and the adverse effects of lamivudine treatment were also recorded.

Results: Following 8 weeks of lamivudine treatment, HBV viral load decreased to levels ≤ 10,000 copies/ml in five of the seven patients (71%) and in three patients (43%), HBV DNA was found to be completely negative after labor. Neither adverse effects caused by lamivudine treatment nor complications due to CHB infection were experienced by mothers or infants.

Conclusions: The results of this study suggest that lamivudine therapy in highly viremic hepatitis B surface antigen (HBsAg)-positive pregnant women could decrease perinatal transmission rates of HBV, and can lower the HBV viral load during labor.

Author Biographies

Sükran Köse, Tepecik Training and Research Hospital, Department of Infectious Diseases and Clinic Microbiology, Turkey

Department of Infectious Tepecik Training and Research Hospital, Department of Infectious Diseases and Clinic Microbiology

Melda Türken, Tepecik Training and Research Hospital, Department of Infectious Diseases and Clinic Microbiology, Turkey

Department of Infectious Tepecik Training and Research Hospital, Department of Infectious Diseases and Clinic Microbiology

İlker Devrim, Pediatric Infectious Disease Unit

Pediatric Infectious Disease Unit, Dr. Behcet Uz Children's Hospital

Cüneyt Taner, izmir Aegean Obstetrics and Gynecology Teaching Hospital, Izmir, Turkey

Izmir Aegean Obstetrics and Gynecology Teaching Hospital, Izmir, Turkey

Downloads

Published

2011-03-04

How to Cite

1.
Köse S, Türken M, Devrim İlker, Taner C (2011) Efficacy and safety of lamivudine treatment in late pregnancy with high HBV DNA: a perspective for mother and infants. J Infect Dev Ctries 5:303–306. doi: 10.3855/jidc.1398

Issue

Vol. 5 No. 04: April 2011

Section

Brief Original Articles

License

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
Crossref
Scopus
Google Scholar
Europe PMC